Skip to ContentSkip to Navigation
About us Latest news News News articles

Antibody can halt effect of new anticoagulants

22 June 2015
Research University Medical Center Groningen

For the first time, scientists have managed to counteract a significant disadvantage of new anticoagulants. In an international study, they have discovered an antibody that can temporarily halt the effect of these blood thinners. Their findings are published today in the influential New England Journal of Medicine. Pieter Willem Kamphuisen, an internist at the UMCG who is on the steering committee of the study, says this is a breakthrough in the use of the new anticoagulants.

New Oral AntiCoagulants (NOACs) is the collective name for a new generation of blood thinners that have been on the market for some years. Their advantage is that people who take them no longer need to have their blood tested for thrombosis. A major disadvantage is that their effect cannot be halted. This becomes relevant if a patient suffers from a sudden haemorrhage or must be operated on without delay.

Temporarily halt possible

This is the first time that researchers have managed to show that the effect of dabigatran, the most common of the NOACs, can temporarily be halted. They conducted an international study of 90 patients around the world who used the drug and underwent an unexpected operation. Kamphuisen believes that this was the real test of whether the antibody would work. ‘The antibody proved to work rapidly and there were no other disadvantageous effects such as extra blood clotting or thrombosis’.

Global research

The next stage in the research involves testing the antibody on a further three hundred patients. As Kamphuisen is on the steering committee of the study, some of this global research will be conducted in the UMCG. The next stage will take some time, says Kamphuisen, who is currently presenting the results of the study at a conference in Toronto. This is because it is impossible to predict when suitable patients will present themselves.

About 400,000 people in the Netherlands use anticoagulants. They are mainly patients with heart disease, thrombosis or an artificial heart valve, and they must generally continue to take these for the rest of their lives.

Noot voor de pers

Contact: via the UMCG Press Office, phone +3150 361 22 00

Last modified:12 March 2020 9.47 p.m.
View this page in: Nederlands

More news

  • 25 April 2023

    KNAW appoints Marrink and Rosmalen as members

    The Royal Netherlands Academy of Arts and Sciences (KNAW) has appointed Professor Siewert-Jan Marrink and Professor Judith Rosmalen as members of the Academy. Members of the KNAW, prominent academics from all disciplines, are chosen on the basis of...

  • 13 April 2023

    Ontregeld en onzeker: UMCG-onderzoek geeft inzicht in gevolgen post-COVID

    Mensen met post-COVID ervaren levensveranderende beperkingen. Ze zijn mentaal en fysiek ontregeld, ervaren veel onzekerheid en de impact op hun dagelijks leven is groot. Dit blijkt uit onderzoek van het UMCG naar de persoonlijke en maatschappelijke...

  • 11 April 2023

    Three promising UG researchers to top institutes abroad on Rubicon grants

    Three promising PhD graduates from the University of Groningen will be able to conduct research at top institutes abroad for two years thanks to the Rubicon programme organized by the Netherlands Organisation for Scientific Research (NWO) and...